Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ultrafast, Low-Cost Point-of-Care PCR Testing System Provides Central Lab Precision in 15 Minutes

By LabMedica International staff writers
Posted on 16 May 2023

Despite the rapid progress in medical testing, there's still a pressing demand for improved diagnostic and screening tools for infectious bacterial and viral pathogens. More...

Currently, nucleic acid amplification tests (NAAT), such as RT-PCR, are the “gold standard” for accuracy, with the highest analytic sensitivity. However, PCR testing requires specialized lab equipment, significant technical knowledge, and is costly, time-intensive, and often inaccessible in remote or under-resourced areas. Now, a compact, portable platform that can be operated by non-technical personnel takes testing out of the traditional laboratory environment by consolidating the entire PCR testing process (sample extraction and PCR), providing results in approximately 15 minutes.

The DASH (Diagnostic Analyzer for Specific Hybridization) quantitative PCR system from Minute Molecular Diagnostics (Evanston, IL, USA) is roughly the size of a cereal box, making it compact enough to fit on a countertop or desk. DASH delivers the same accuracy as other PCR tests in a compact portable platform that can be utilized by non-technical personnel at the point of care. It identifies infectious bacterial and viral pathogens in under 15 minutes, requiring less than a minute of hands-on time. During the initial 10 minutes, samples are extracted and purified with sequence-specific capture probes. Paramagnetic particles (PMP) are introduced to bind to the target probe complex. Subsequently, the targets are magnetically separated from the swab extraction buffer, cleaned, and moved to the PCR chamber. During the final five minutes of the assay, 40 PCR temperature cycles are executed, with fluorescence measured via a four-channel optical system.

DASH's defining features are its user-friendly nature, quickness, and PCR-level precision. The DASH interface guides users through each step, making it as simple to operate as a coffee machine. Although initially conceived to combat the COVID-19 pandemic, the technology is versatile, capable of detecting a range of viral and bacterial pathogens. Presently, Minute Molecular Diagnostics is working on developing similar tests for influenza, HIV, Hepatitis C, several sexually transmitted diseases, MRSA, and C. diff, compatible with various sample types, including nasal swabs, saliva, and blood. The DASH PCR testing system can also provide a quantitative report of HIV and Hepatitis C viral loads. Its compact size facilitates testing in hospital and non-hospital settings. DASH units can be linked together to deliver between 4 and 24 test results per hour, making it an excellent choice for point-of-care testing in clinics, businesses, or community environments.

Related Links:
Minute Molecular Diagnostics 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.